Hyphens Pharma International Ltd. · SGX:1J5
Hyphens Pharma International — H1 2023 Earnings Presentation
17 slides from Hyphens Pharma International's earnings presentation, Aug 17, 2023
Slide 1: General Announcement: Results Briefing 1H 2023
8/17/23, 12:31 PM General Announcement::RESULTS BRIEFING 1H 2023 GENERAL ANNOUNCEMENT::RESULTS BRIEFING 1H 2023 Issuer & Securities Issuer/ Manager HYPHENS PHARMA INTERNATIONAL LIMITED Securities HYPHENS PHARMA INTL LIMITED - SG1EE4000006 - 1J5 Stapled Security No Announcement Details Announcement T
Slide 2: Hyphens Pharma International Limited Results Briefing 1H 2023
HYPHENS PHARMA INTERNATIONAL LIMITED Results Briefing 1H 2023 17 AUG 2023
Slide 3: Disclaimer
DISCLAIMER This presentation has been prepared by Hyphens Pharma International Limited (the "Company" and, together with its subsidiaries, the "Group"). This content in this presentation is being furnished to you on a confidential basis and solely for your information and neither this presentation n
Slide 4: Business Updates
uu e _J > Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group g Hyphens
Slide 5: 1.1 New Additions to the Portfolio
1.1 NEW ADDITIONS TO THE PORTFOLIO WE ACTIVELY SEEK NEW LICENSING OPPORTUNITIES TO PROVIDE A WIDER RANGE OF PRODUCTS TO OUR CUSTOMERS We have added the following products to our Singapore portfolio: Products from Laboratoires Gilbert S.A.S. in the territories of Hong Kong, Laos, Mongolia, Singapore,
Slide 6: 1.2 New Leadership Joined the Company
1.2 NEW LEADERSHIP JOINED THE COMPANY WE ARE EXCITED TO HAVE NEW TALENTS TO JOIN US FOR THE NEXT STAGE OF GROWTH RACHIT VOHRA FLORA ZHANG LAURENCE FREMY VP, Strategy & Business Chief Financial Officer Vietnam Country Development Manager
Slide 7: 1.3 DocMed Updates
1.3 DOCMED UPDATES DOCMED LAUNCHED ITS JOINT VENTURE IN VIETNAM AND OPENED ITS MALAYSIA BUSINESS TECHMED
Slide 8: Financial Results
Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group g Hyphens
Slide 9: 2.1 Financial Performance
2.1 FINANCIAL PERFORMANCE WE HAVE SHOWN RESILIENCE IN AN ENVIRONMENT FILLED WITH VOLATILITY AND UNCERTAINTY Revenue (S$’m) Profit After Tax (S$’m) 80.7 81.6 6.2 74.7 5.2 61.5 63.8 62.1 60.4 60.6 54.8 4.2 3.5 3.4 3.5 3.1 2.5 1.0 * Excl JSS
Slide 10: 2.2 Financial Performance by Quarter
2.2 FINANCIAL PERFORMANCE BY QUARTER WE HAVE ACHIEVED HIGH GROWTH QOQ IN Q2 AND ARE GETTING OURSELVES READY FOR H2 Revenue (S$’m) Profit After Tax (S$’m) 45.0 42.8 4.5 41.5 41.5 39.2 38.8 4.0 40.0 4.0 35.0 33.2 3.5 3.2 3.0 30.0 3.0 25.0 2.5 2.1 20.0 2.0 1.4 15.0 1.5 1.1 10.0 1.0 5.0 0.5 - - 1Q2022 2
Slide 11: 2.3 Revenue by Business Segments
2.3 REVENUE BY BUSINESS SEGMENTS PROPRIETARY BRANDS SHOW HEALTHY GROWTH YOY; SPECIALTY PHARMA SETS ON NEW GROWTH TRAJECTORY 45.0 40.0 35.0 Revenue in S$m 30.0 60% 59% 60% 60% 57% 25.0 52% 20.0 15.0 17% 13% 14% 14% 17% 15% 10.0 5.0 28% 26% 25% 28% 31% 26% - 1Q2022 2Q2022 3Q2022 4Q2022 1Q2023 2Q 2023
Slide 12: 2.4 Income Statement
2.4 INCOME STATEMENT WE ARE CONFIDENT WITH THE BUSINESS FUNDAMENTALS, AND WE FUEL RESOURCES FOR THE NEXT PHASE OF GROWTH 1H2023 vs 1H2022 YoY ex • Revenue suffered from loss of 1H2023 1H2022 YoY Biosensors Biosensors sales and supply chain disruptions. S$000 S$000 % % Revenue 74,711 80,704 -7% -2% •
Slide 13: 2.5 Rewarding Shareholders
2.5 REWARDING SHAREHOLDERS Dividend Yield FY2023 3.60 cents (a) 12.4%(b) FY2022 1.11 cents 3.4%(c) (a) Special interim dividends as part of 5th anniversary celebration since IPO. (b) Yield is computed based on total dividends declared for the financial period divided by closing price of S$0.29 @ 8 A
Slide 14: Business Outlook
Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group g Hyphens
Slide 15: 3 Acceleration for Growth
3 ACCELERATION FOR GROWTH + Grow our proprietary brands business + Grow the specialty pharma portfolio + Build medical aesthetics as an allied category to the Derma Business + Inorganic growth
Slide 16: Questions & Answers
Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group g Hyphens
Slide 17: Hyphens Pharma International Limited (SGX: 1J5)
Hyphens Pharma International Limited (SGX: 1J5) 16 Tai Seng Street, Level 4, Singapore 534138 www.hyphensgroup.com
Hyphens Pharma International — H1 2023 Earnings Presentation on 6ix